Lineage Cell Therapeutics Files 'Other Events' 8-K

TL;DR

Lineage Cell Therapeutics filed an 8-K for an 'Other Event' on Feb 14, but specific details aren't in this snippet.

AI Summary

Lineage Cell Therapeutics, Inc. filed an 8-K with the SEC on February 15, 2024, reporting an "Other Event" that occurred on February 14, 2024. This regulatory filing, identified by accession number 0001493152-24-006901, indicates a material development, though the specific details of the event are not provided in this excerpt. The company's business address is 2173 Salk Avenue, Suite 200, Carlsbad, California.

Why It Matters

8-K filings are crucial for investors as they disclose material events that could impact a company's stock price or operations. While the specific event details are not provided here, the filing signals that Lineage Cell Therapeutics, Inc. has a development it deems important enough to report to the SEC.

Risk Assessment

Risk Level: low — The filing itself is a standard regulatory disclosure of an 'Other Event' without specific details provided, thus not indicating immediate financial risk from the document's content.

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — filer
• February 14, 2024 (date) — date of earliest event reported
• February 15, 2024 (date) — filed as of date
• SEC (company) — regulatory body

FAQ

Filing Documents

• form8-k.htm (8-K) — 34KB
• 0001493152-24-006901.txt ( ) — 203KB
• lctx-20240214.xsd (EX-101.SCH) — 3KB
• lctx-20240214_lab.xml (EX-101.LAB) — 33KB
• lctx-20240214_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. The 2024 annual meeting of shareholders (the "Annual Meeting") of Lineage Cell Therapeutics, Inc. (the "Company") is scheduled to be held on June 11, 2024, which is more than 30 days before the one-year anniversary of the Company's 2023 annual meeting of shareholders. In light of the foregoing, and in accordance with the Company's amended and restated bylaws (the "Bylaws"), in order for any business to be brought before the Annual Meeting by a shareholder and for any person to be nominated for election to the Company's board of directors at the Annual Meeting by a shareholder, such shareholder must notify the Company of such intention by notice received at the Company's principal executive offices not later than the close of business on March 15, 2024. Shareholder proposals intended for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), must be received at the Company's principal executive offices no later than the close of business on March 29, 2024, which the Company believes is a reasonable time before it begins to print and mail proxy materials for the Annual Meeting. In addition, all such shareholder notices and shareholder proposals must conform to the applicable requirements of the Bylaws, the rules and regulations promulgated under the Exchange Act and other applicable law. All such notices and shareholder proposals are be directed to: "Lineage Cell Therapeutics, Inc., 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008, Attention: Corporate Secretary."

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lineage Cell Therapeutics, Inc. Date: February 15, 2024 By: /s/ George A. Samuel III Name: George A. Samuel III Title: General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR